Michael Byrnes, CFO at eFFECTOR Therapeutics, provides a prequel to an upcoming two-part article in Life Science Leader, with some specific recommendations for executive teams on SPACs.
Nobert Bischofberger, Ph.D., CEO of Kronos Bio, reflects on lessons learned from an important mentor and biotech icon.
Laura Niklason, M.D., Ph.D., cofounder and CEO of Humacyte, explains some of the science of her regenerative medicines company so to be public via a SPAC.
A primer on what makes Eric Dube, Ph.D., CEO of Travere Therapeutics and upcoming feature in Life Science Leader, so inspirational.
An interview with Mei Mei Hu, cofounder and CEO of Vaxxinity, provides an example of how COVID-19 and Zoom have enabled the seeing and showing of one another’s humanness.
John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
Neil Kumar, cofounder and CEO of BridgeBio, discusses his rationale behind why employees didn’t have titles during the startup phase.
Neil Kumar, cofounder and CEO of BridgeBio, a company today valued at more than $10 billion, shares an embarrassing experience of the startup’s humble beginnings.
John Fowler’s atypical path to becoming a biopharmaceutical company cofounding CEO, began in Congress, along with a decade spent leading companies in completely different industries.
Joseph Wolk, J.D., C.P.A, CFO of Johnson & Johnson (J&J), discusses how the CFO role has evolved from the days of monitoring debits and credits.
Get the latest articles from Life Science Leader delivered to your inbox.